`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`REGENERON PHARMACEUTICALS, INC.
`Petitioners,
`v.
`NOVARTIS PHARMA AG, NOVARTIS TECHNOLOGY LLC, NOVARTIS
`PHARMACEUTICALS CORPORATION.
`Patent Owners.
`
`IPR2021-00816
`Patent No. 9,220,631
`
`DECLARATION OF DANIEL P. MARGOLIS IN SUPPORT OF PATENT
`OWNERS’ MOTION FOR PRO HAC VICE ADMISSION OF DANIEL P.
`MARGOLIS UNDER 37 C.F.R. § 42.10(c)
`
`Mail Stop PATENT BOARD
`Patent Trial and Appeal Board
`United States Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Novartis Exhibit 2334.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`I, Daniel P. Margolis, declare as follows:
`
`1.
`
`I obtained a B.S. in Chemical Engineering from Rutgers University
`
`College of Engineering in 1998, a Ph.D. in Chemical Engineering from Carnegie
`
`Mellon University in 2003, and a J.D. from New York University School of Law in
`
`2006.
`
`2.
`
`I am currently a partner in the law firm of Allen & Overy LLP, a
`
`position I have held since 2022. In my fifteen years of practice, I have focused
`
`primarily on representing clients in patent litigations involving the chemical arts in
`
`United States district courts, the Court of Appeals for the Federal Circuit, and in
`
`the United States International Trade Commission. Through this work, I have
`
`gained extensive experience as a litigating attorney, particularly in patent cases.
`
`3.
`
`I am a member in good standing of the Bar of the State of New York,
`
`and am admitted to practice before the United States District Court for the
`
`Southern District of New York and the United States District Court for the
`
`Northern District of New York.
`
`4.
`
`In the last three years, I have been admitted to appear pro hac vice
`
`before the Patent Trial and Appeal Board in PGR 2021-00006, IPR 2021-01024,
`
`IPR 2021-01025, IPR2021-01288, and IPR2021-01336. I also have applied for
`
`pro hac vice admission in IPR2021-01542 and IPR2022-00201.
`
`Novartis Exhibit 2334.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`5.
`
`I have substantial familiarity with the subject matter at issue in this
`
`proceeding. Petitioner has challenged U.S. Patent No. 9,220,631 (“the ’631
`
`patent”), the patent at issue in this proceeding. I have developed a strong
`
`familiarity with the ’631 patent, its prosecution history, the general subject matter
`
`to which the ’631 patent is directed, and the prior art references relied upon by
`
`Petitioner in support of its Papers. Furthermore, I have thoroughly reviewed the
`
`Petition and accompanying Exhibits submitted in this proceeding.
`
`6.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`7.
`
`I have never had an application for admission to practice before any
`
`court or administrative body denied.
`
`8.
`
`I have never been subject to any sanction or contempt citation
`
`imposed by any court or administrative body.
`
`9.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
`
`10.
`
`I agree to be subject to the USPTO Rules of Professional Conduct set
`
`forth in 37 C.F.R. §§ 11.101 et. seq. and disciplinary jurisdiction under 37 C.F.R. §
`
`11.19(a).
`
`11.
`
`I declare under penalty of perjury that the foregoing is true and
`
`correct. I further declare that all statements made herein of my own knowledge are
`
`Novartis Exhibit 2334.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`true and that all statements made on information and belief are believed to be true;
`
`and further that these statements were made with the knowledge that willful false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under section 1001 of title 18 of the United States Code, and that such willful false
`
`statements may jeopardize the validity of the application or any patent issued
`
`thereon.
`
`Executed on: March 24, 2022
`
`/Daniel P. Margolis/
`Daniel P. Margolis
`
`Novartis Exhibit 2334.004
`Regeneron v. Novartis, IPR2021-00816
`
`